Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2024-204878

Published: 2024

Journal Articles

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2024-210920

Published: 2024

Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst

Blood (2024) 143 (13): 1269–1281.

https://doi.org/10.1182/blood.2023021815

Published: 2024

Includes: Supplemental data

Journal Articles

Prednisolone Intake Differentially Regulates IL12p40 and IL18 - Impact on Severe Chronic Gvhd, Relapse and Mortality

Salim Oulghazi, Leonard Petry, Mark E Robinson, Richard Huth, Caroline Pabst, Peter Dreger, Thomas Luft

Blood (2023) 142 (Supplement 1): 3557.

https://doi.org/10.1182/blood-2023-180784

Published: 2023

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Blood (2022) 140 (Supplement 1): 3317–3319.

https://doi.org/10.1182/blood-2022-167677

Published: 2022

Journal Articles

Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo

Karin Prummel, Anna Mathioudaki, Lixiazi He, Shubhankar Sood, Rim Moussa, Robert Reinhardt, Swati Garg, Simon Haas, Marieke Essers, Sinem K Saka, Caroline Pabst, Judith Zaugg

Blood (2022) 140 (Supplement 1): 5770–5771.

https://doi.org/10.1182/blood-2022-170377

Published: 2022

Journal Articles

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina

Blood (2022) 140 (Supplement 1): 9087–9088.

https://doi.org/10.1182/blood-2022-159471

Published: 2022

Journal Articles

Interleukin-12 and Interleukin-18 Associate with Chronic Graft-Versus-Host Disease but with Inverse Clinical Outcomes

Thomas Luft, Salim Oulghazi, Caroline Pabst, Leonard Petry, Richard Huth, Carsten Müller-Tidow, Peter Dreger

Blood (2022) 140 (Supplement 1): 7641–7642.

https://doi.org/10.1182/blood-2022-163269

Published: 2022

Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6224–6225.

https://doi.org/10.1182/blood-2022-157833

Published: 2022

Journal Articles

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Blood (2021) 138 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2021-151287

Published: 2021

Journal Articles

The Ribomethylome Landscape of Hematopoietic System

Yanyan Wang, Christian Rohde, PhD, Fengbiao Zhou, PhD, Marco Hennrich, PhD, Laura Poisa-Beiro, PhD, Volker Eckstein, PhD, Caroline Pabst, MD, Anne-Claude Gavin, PhD, Anthony D Ho, MD, Carsten Müller-Tidow, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136522

Published: 2020

Journal Articles

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation

Cornelius Pauli, Yi Liu, Christian Rohde, Chunhong Cui, Daria Fijalkowska, Dennis Gerloff, Carolin Walter, Jeroen Krijgsveld, Martin Dugas, Bayram Edemir, Caroline Pabst, Lutz P. Müller, Fengbiao Zhou, Carsten Müller-Tidow

Blood (2020) 135 (23): 2059–2070.

https://doi.org/10.1182/blood.2019004121

Published: 2020

Includes: Supplemental data

Journal Articles

Cooperating mutations: joint forces, novel vulnerabilities

Caroline Pabst

Blood (2020) 135 (11): 785–787.

https://doi.org/10.1182/blood.2019004679

Published: 2020

Journal Articles

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Blood (2019) 134 (3): 263–276.

https://doi.org/10.1182/blood.2018862383

Published: 2019

Includes: Supplemental data

Journal Articles

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2018-99-116256

Published: 2018

Journal Articles

Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors

Vincent-Philippe Lavallée, Jana Krosl, Sébastien Lemieux, Geneviève Boucher, Patrick Gendron, Caroline Pabst, Isabel Boivin, Anne Marinier, Cynthia J. Guidos, Sylvain Meloche, Josée Hébert, Guy Sauvageau

Blood (2016) 127 (24): 3054–3061.

https://doi.org/10.1182/blood-2016-03-705053

Published: 2016

Includes: Supplemental data

Journal Articles

GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo

Blood (2016) 127 (16): 2018–2027.

https://doi.org/10.1182/blood-2015-11-683649

Published: 2016

Includes: Supplemental data

Journal Articles

The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia

Caroline Pabst, MD, Anne Bergeron, PhD, Vincent-Philippe Lavallée, MD, Jonathan Yeh, PhD, Patrick Gendron, M.Sc, Jana Krosl, PhD, Geneviève Boucher, M.Sc, Sébastien Lemieux, PhD, Josee Hébert, MD, Guy Sauvageau, MD, PhD, Frédéric Barabé, MD

Blood (2015) 126 (23): 1859.

https://doi.org/10.1182/blood.V126.23.1859.1859

Published: 2015

Journal Articles

Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia

Arhamatoulaye Maiga, PhD, Sébastien Lemieux, PhD, Caroline Pabst, MD, Vincent-Philippe Lavallée, MD, Michel Bouvier, PhD, Guy Sauvageau, MD, PhD, Josée Hébert, MD

Blood (2015) 126 (23): 3855.

https://doi.org/10.1182/blood.V126.23.3855.3855

Published: 2015

NARROW

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Prednisolone Intake Differentially Regulates IL12p40 and IL18 - Impact on Severe Chronic Gvhd, Relapse and Mortality

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Interleukin-12 and Interleukin-18 Associate with Chronic Graft-Versus-Host Disease but with Inverse Clinical Outcomes

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

The Ribomethylome Landscape of Hematopoietic System

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation

Cooperating mutations: joint forces, novel vulnerabilities

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors

GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo

The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia

Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only